Status:
TERMINATED
Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy
Lead Sponsor:
Emory University
Conditions:
Urolithiasis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The majority of kidney stones are treated with shock wave lithotripsy (SWL). We are examining if the medication Flomax will result in improved stone passage rates following SWL.
Detailed Description
Placebo blinded study examining the effects of Flomax on stone passage rates following SWL.
Eligibility Criteria
Inclusion
- Patients 18 years old and above with urolithiasis scheduled for shock wave lithotripsy.
Exclusion
- Contraindications to Flomax
- Patients with renal impairment (serum creatinine above 2.0)
- Patients with hepatic impairment (liver enzymes 2.5 times the upper limit of normal)
- Use of other oral alpha blockers
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00209131
Start Date
April 1 2005
End Date
February 1 2009
Last Update
October 28 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Emory University
Atlanta, Georgia, United States, 30322